DICE News and Press, DICE Therapeutics Inc. From 01/04/23

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic ...

DICE Therapeutics press release ( NASDAQ: DICE ): Q3 GAAP EPS of -$0.55 beats by $0.05 . Cash, cash equivalents and marketable securities totaled $266.6 million at September 30, 2022. In addition, in October 2022, DICE announced the successful closing of an upsized...

Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasis Demonstrated direct inhibition of a cytokine with a small molecule in psoriasis patients, which we believe vali...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

Summary DICE Therapeutics is a recent IPO. Recently, it came out with positive data from its lead asset. There are many hurdles to cross, but they have crossed the first hurdle quite convincingly. DICE Therapeutics ( DICE ) is a small molecule therapeutic develop...

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

Biopharmaceutical company DICE Therapeutics ( NASDAQ: DICE ) has priced its upsized offering of 8,219,178 shares of its common stock at $36.50/share. Underwriters have been granted a 30-day option to purchase up to an additional 1,232,876 shares of its common stock at the ...

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

Dice Therapeutics ( NASDAQ: DICE ) announced Tuesday that it has started off $250M public stock offering; actual size and terms of the transaction yet not determined. The California-based biopharma company said underwriters have been granted an overallotment option to purc...

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...